Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7021 to 7035 of 7675 results

  1. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    In development [GID-TA10583] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued [GID-TA10739]

    Technology appraisal guidance
    Discontinued

  3. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued [GID-TA10382]

    Technology appraisal guidance
    Discontinued

  4. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued [GID-TAG332]

    Technology appraisal guidance
    Discontinued

  5. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued [GID-TAG418]

    Technology appraisal guidance
    Discontinued

  6. Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

    Discontinued [GID-TA10337]

    Technology appraisal guidance
    Discontinued

  7. Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

    Discontinued [GID-TA10236]

    Technology appraisal guidance
    Discontinued

  8. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued [GID-TAG397]

    Technology appraisal guidance
    Discontinued

  9. Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]

    Discontinued [GID-TA10159]

    Technology appraisal guidance
    Discontinued

  10. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued [GID-TA10803]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued [GID-TA10380]

    Technology appraisal guidance
    Discontinued

  12. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued [GID-TA11151]

    Technology appraisal guidance
    Discontinued

  13. Venous thromboembolism (VTE) - ximelagatran [ID396]

    Discontinued [GID-TAG378]

    Technology appraisal guidance
    Discontinued

  14. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued [GID-TA11171]

    Technology appraisal guidance
    Discontinued

  15. Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]

    In development [GID-TA11107] Expected publication date: TBC

    Technology appraisal guidance
    In development